Gastrointestinal Stromal Tumors
Specialty Channel

Featured Article
INVICTUS study results reveal intra-patient dose escalation (IPDE) of ripretinib after disease progression indicate clinical benefit and tolerability in patients with advanced gastrointestinal…
Investigators sought to determine if chromosomal complexity could be used as a biomarker in de-escalation of adjuvant imatinib treatment, presented at the 2021 ASCO Annual Meeting. 
A phase III trial evaluated the efficacy and safety of pimitesib in patients with advanced GIST refractory to standard treatments, whose medical requirements remain unmet, presented at the 2021 ASCO…
Results following the phase Ib portion in the evaluation of imatinib in combination with selinexor displays well tolerability in patients with imatinib (IM)-resistant, advanced GIST, presented at the…
True or False: Findings from a retrospective analysis suggest the clinical features and treatment approaches for multiple gastrointestinal stromal tumors (MGISTs) may differ from single GISTs,…
True or False: A genetic diagnosis yields benefit in gastrointestinal stromal tumor therapy by informing the patient and provider(s) of the possibility for other malignancies, suggested surveillance…
A patient case study, presented at the 2021 ONS Congress, supports the confirmation that a genetic diagnosis leads to the appropriate management and surveillance approach in GIST, NF1 and other…
True or False: Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.
True or false: Prolonged adjuvant imatinib therapy extends overall survival in patients with high-risk GIST.

News

INVICTUS study results reveal intra-patient dose escalation (IPDE) of ripretinib after disease progression indicate clinical benefit and tolerability in patients with advanced gastrointestinal…
Investigators sought to determine if chromosomal complexity could be used as a biomarker in de-escalation of adjuvant imatinib treatment, presented at the 2021 ASCO Annual Meeting. 
A phase III trial evaluated the efficacy and safety of pimitesib in patients with advanced GIST refractory to standard treatments, whose medical requirements remain unmet, presented at the 2021 ASCO…
Results following the phase Ib portion in the evaluation of imatinib in combination with selinexor displays well tolerability in patients with imatinib (IM)-resistant, advanced GIST, presented at the…

Interactive Features

True or False: Findings from a retrospective analysis suggest the clinical features and treatment approaches for multiple gastrointestinal stromal tumors (MGISTs) may differ from single GISTs,…
True or False: A genetic diagnosis yields benefit in gastrointestinal stromal tumor therapy by informing the patient and provider(s) of the possibility for other malignancies, suggested surveillance…
True or False: Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.
True or false: Prolonged adjuvant imatinib therapy extends overall survival in patients with high-risk GIST.
Stay in the know.
OncNet Newsletter